Prostanoid receptors and phosphatidylinositol 3-kinase: A pathway to cancer?

Trends in Pharmacological Sciences

Volumn 24, Issue 7, 2003, Pages 335-340

  Fujino, Hiromichi ^a   Regan, John W ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; BETA CATENIN; CYCLOOXYGENASE 2; G PROTEIN COUPLED RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN F; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; PROSTANOID RECEPTOR; RECEPTOR SUBTYPE; UVOMORULIN; PROSTAGLANDIN F2ALPHA RECEPTOR; PROSTAGLANDIN RECEPTOR; PTGIR PROTEIN, HUMAN;

ADENOMATOUS POLYP; COLON CANCER; ENZYME ACTIVATION; ENZYME ACTIVITY; MOLECULAR BIOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; BIOSYNTHESIS; ENZYMOLOGY; HUMAN; METABOLISM; NEOPLASM; PHYSIOLOGY; SECOND MESSENGER;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; HUMANS; NEOPLASMS; RECEPTORS, PROSTAGLANDIN; SECOND MESSENGER SYSTEMS;

EID: 0042734625     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(03)00162-7     Document Type: Article

References (40)

1. Narumiya S., FitzGerald G.A. Genetic and pharmacological analysis of prostanoid receptor function. J. Clin. Invest. 108:2001;25-30.
2. Breyer R.M., et al. Prostanoid receptors: subtypes and signaling. Annu. Rev. Pharmacol. Toxicol. 41:2001;661-690.
3. Narumiya S., et al. Prostanoid receptors: structures, properties, and functions. Physiol. Rev. 79:1999;1193-1226.
4. Pierce K.L., Regan J.W. Prostanoid receptor heterogeneity through alternative mRNA splicing. Life Sci. 62:1998;1479-1483.
5. Marnett L.J., DuBois R.N. COX-2: a target for colon cancer prevention. Annu. Rev. Pharmacol. Toxicol. 42:2002;55-80.
6. Subbaramaiah K., Dannenberg A.J. Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol. Sci. 24:2003;96-102.
7. 2 subtype. Mol. Pharmacol. 46:1994;213-220.
8. 2 subtype. J. Biol. Chem. 269:1994;11873-11877.
9. 4 subtype. FEBS Lett. 364:1995;339-341.
10. Pierce K.L., et al. Cloning of a carboxyl-terminal isoform of the prostanoid FP receptor. J. Biol. Chem. 272:1997;883-887.
11. 4, differ in desensitization and sensitivity to the metabolic inactivation of the agonist. Mol. Pharmacol. 50:1996;1031-1037.
12. 4 receptor sequestration. Mol. Pharmacol. 58:2000;1279-1286.
13. 2α receptor isoforms: role of protein kinase C and clathrin. J. Pharmacol. Exp. Ther. 302:2002;219-224.
14. Fujino H., et al. Cellular conditioning and activation of β-catenin signaling by the FPB prostanoid receptor. J. Biol. Chem. 277:2002;48786-48795.
15. 2. J. Biol. Chem. 277:2002;2614-2619.
16. 2, prostanoid receptors via phosphatidylinositol 3-kinase and the extracellular signal-regulated kinases. J. Biol. Chem. 278:2003;12151-12156.
17. Kobayashi T., Narumiya S. Function of prostanoid receptors: studies on knockout mice. Prostaglandins Other Lipid Mediat. 68-69:2002;557-573.
18. Pierce K.L., et al. Activation of FP prostanoid receptor isoforms leads to Rho-mediated changes in cell morphology and in the cell cytoskeleton. J. Biol. Chem. 274:1999;35944-35949.
19. B prostanoid receptors. Possible role of receptor resensitization. J. Biol. Chem. 275:2000;29907-29914.
20. Fujino H., Regan J.W. FP prostanoid receptor activation of a T-cell factor/β-catenin signaling pathway. J. Biol. Chem. 276:2001;12489-12492.
21. Peifer M., Polakis P. Wnt signaling in oncogenesis and embryogenesis - a look outside the nucleus. Science. 287:2000;1606-1609.
22. Srivastava S., et al. Biomarkers for early detection of colon cancer. Clin. Cancer Res. 7:2001;1118-1126.
23. 2α receptor isoforms by protein kinase C. Mol. Pharmacol. 57:2000;353-358.
24. Araki Y., et al. Regulation of cyclooxygenase-2 expression by the Wnt and Ras pathways. Cancer Res. 63:2003;728-734.
25. 2α stimulation of cyclooxygenase-2 promoter activity by the FPB prostanoid receptor. Eur. J. Pharmacol. 465:2003;39-41.
26. Dhillon A.S., et al. Cyclic AMP-dependent kinase regulates Raf-1 kinase mainly by phosphorylation of serine 259. Mol. Cell. Biol. 22:2002;3237-3246.
27. Sidovar M.F., et al. Phosphorylation of serine 43 is not required for inhibition of c-Raf kinase by the cAMP-dependent protein kinase. J. Biol. Chem. 275:2000;28688-28694.
28. Petiot A., et al. Distinct classes of phosphatidylinositol 3′-kinases are involved in signaling pathways that control macroautophagy in HT-29 cells. J. Biol. Chem. 275:2000;992-998.
29. Phillips W.A., et al. Increased levels of phosphatidylinositol 3-kinase activity in colorectal tumors. Cancer. 83:1998;41-47.
30. Chung D.C. The genetic basis of colorectal cancer: insights into critical pathways of tumorigenesis. Gastroenterology. 119:2000;854-865.
31. 4 in colon carcinogenesis. Cancer Res. 62:2002;28-32.
32. 2 increases growth and motility of colorectal carcinoma cells. J. Biol. Chem. 276:2001;18075-18081.
33. Asano T., et al. Expression of cyclooxygenase-2 and prostaglandin E-receptors in carcinoma of the gallbladder: crucial role of arachidonate metabolism in tumor growth and progression. Clin. Cancer Res. 8:2002;1157-1167.
34. 1A cells. J. Biol. Chem. 276:2001;39394-39403.
35. 2 synthase gene. Essential role of the transcription factor Egr-1. J. Biol. Chem. 277:2002;28601-28608.
36. Yoshimatsu K., et al. Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer. Clin. Cancer Res. 7:2001;3971-3976.
37. Δ716 knockout mice. Nat. Med. 7:2001;1048-1051.
38. 1 in colon carcinogenesis. Cancer Res. 59:1999;5093-5096.
39. 3 signaling regulates tumor-associated angiogenesis and tumor growth. J. Exp. Med. 197:2003;221-232.
40. Chulada P.C., et al. Genetic disruption of Ptgs-1, as well as of Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res. 60:2000;4705-4708.